NP_001809.3
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Primary Accession #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
37,067 Da
NCBI Official Full Name
aldo-keto reductase family 1 member C4
NCBI Official Synonym Full Names
aldo-keto reductase family 1, member C4
NCBI Official Synonym Symbols
C11; CDR; DD4; CHDR; DD-4; HAKRA; 3-alpha-HSD [Similar Products]
NCBI Protein Information
aldo-keto reductase family 1 member C4
UniProt Protein Name
Aldo-keto reductase family 1 member C4
UniProt Synonym Protein Names
3-alpha-HSD1; 3-alpha-hydroxysteroid dehydrogenase type I (EC:1.1.1.357); Chlordecone reductase (EC:1.1.1.225); CDR; Dihydrodiol dehydrogenase 4; DD-4; DD4; HAKRA
UniProt Synonym Gene Names
UniProt Entry Name
AK1C4_HUMAN
NCBI Summary for AKR1C4
This gene encodes a member of the aldo/keto reductase superfamily, which consists of more than 40 known enzymes and proteins. These enzymes catalyze the conversion of aldehydes and ketones to their corresponding alcohols by utilizing NADH and/or NADPH as cofactors. The enzymes display overlapping but distinct substrate specificity. This enzyme catalyzes the bioreduction of chlordecone, a toxic organochlorine pesticide, to chlordecone alcohol in liver. This gene shares high sequence identity with three other gene members and is clustered with those three genes at chromosome 10p15-p14. [provided by RefSeq, Jul 2008]
UniProt Comments for AKR1C4
AKR1C4: Catalyzes the transformation of the potent androgen dihydrotestosterone (DHT) into the less active form, 5-alpha- androstan-3-alpha,17-beta-diol (3-alpha-diol). Also has some 20- alpha-hydroxysteroid dehydrogenase activity. The biotransformation of the pesticide chlordecone (kepone) to its corresponding alcohol leads to increased biliary excretion of the pesticide and concomitant reduction of its neurotoxicity since bile is the major excretory route. Defects in AKR1C4 are a cause of 46,XY sex reversal type 8 (SRXY8). A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females. AKR1C4 mutations may act as modifier of disease severity in SRXY8 patients. A splicing mutation resulting in loss of exon 2 has been found in affected individuals also carrying mutation Val-79 in AKR1C2 (PubMed:21802064). Belongs to the aldo/keto reductase family.
Protein type: Lipid Metabolism - androgen and estrogen; Lipid Metabolism - C21-steroid hormone; EC 1.1.1.357; EC 1.1.1.225; Oxidoreductase; Xenobiotic Metabolism - metabolism by cytochrome P450; Lipid Metabolism - primary bile acid biosynthesis
Chromosomal Location of Human Ortholog: 10p15.1
Cellular Component: cytoplasm; cytosol
Molecular Function: 3(or 17)-alpha-hydroxysteroid dehydrogenase activity; aldo-keto reductase activity; bile acid transmembrane transporter activity; chlordecone reductase activity; electron carrier activity; oxidoreductase activity, acting on NADH or NADPH, quinone or similar compound as acceptor; retinal dehydrogenase activity
Biological Process: androgen metabolic process; bile acid and bile salt transport; bile acid biosynthetic process; bile acid metabolic process; fat-soluble vitamin metabolic process; phototransduction, visible light; retinoid metabolic process; steroid metabolic process; vitamin metabolic process
Disease: 46,xy Sex Reversal 8
Research Articles on AKR1C4
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with anti-AKR1C4 antibody
Pathways associated with anti-AKR1C4 antibody
Diseases associated with anti-AKR1C4 antibody
Organs/Tissues associated with anti-AKR1C4 antibody
|